Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx202
Abstract: Abstract Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2… read more here.
Keywords: risks ruxolitinib; ruxolitinib stat1; stat1 gain; gain function ... See more keywords